Micafungin Teva

Micafungin, the active ingredient in Micafungin Teva, is an echinocandin antifungal presented as an intravenous solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis and is used for prophylaxis of Candida infections in hematopoietic stem cell transplantation.

GNH USA supplies Micafungin Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Micafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis.

Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. Esophageal candidiasis: resolves Candida infection of the esophagus. Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infections in transplant recipients.

Common Side Effects: - Fever or chills during infusion - Nausea or vomiting - Headache - Infusion‑related erythema or rash - Elevated liver enzymes (ALT, AST) - Mild hypotension

Serious or Rare Side Effects: - Severe hepatic dysfunction or hepatitis - Anaphylactic or severe allergic reactions - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe hypotension or shock - Acute renal failure - Cardiac arrhythmias

Micafungin should be used with careful clinical monitoring.

Renal impairment: monitor renal function and adjust therapy as needed. Hepatic dysfunction: assess liver enzymes before and during treatment. Concomitant azole therapy: evaluate for potential pharmacokinetic interactions. Pregnancy: safety not established; use only if benefit outweighs risk. Breastfeeding: unknown excretion; consider risk to infant. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Micafungin may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) may reduce micafungin exposure. - CYP3A4 inhibitors (e.g., ketoconazole) may increase micafungin levels. - Co‑administration with other echinocandins can increase toxicity risk.

Moderate Interactions (Monitor Closely): - Concurrent use with warfarin may affect INR; monitor coagulation. - Immunosuppressants such as cyclosporine may require dose adjustment. - Drugs that prolong QT interval may need cardiac monitoring.